Alliance Pharma To Acquire Cambridge Laboratories
The company gains right to 18 prescription drugs through this acquisition, which includes ImmuCyst, an immunotherapy for superficial bladder cancer; gelclair, an oral gel for the management of
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).